Research analysts at Brookline Capital Management assumed coverage on shares of iBio (NYSE:IBIO – Get Free Report) in a research report issued to clients and investors on Monday, Benzinga reports. The firm set a “buy” rating and a $3.60 price target on the stock. Brookline Capital Management’s price target indicates a potential upside of 63.64% from the company’s current price.
Several other equities analysts also recently issued reports on IBIO. StockNews.com initiated coverage on iBio in a research report on Saturday, April 20th. They issued a “sell” rating for the company. Chardan Capital restated a “buy” rating and set a $5.00 target price on shares of iBio in a research report on Monday, June 3rd.
View Our Latest Stock Report on IBIO
iBio Price Performance
iBio (NYSE:IBIO – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.71) EPS for the quarter. As a group, equities analysts expect that iBio will post -99.82 EPS for the current year.
Institutional Investors Weigh In On iBio
A number of institutional investors have recently made changes to their positions in the stock. Lynx1 Capital Management LP acquired a new position in iBio in the first quarter valued at about $2,436,000. Ikarian Capital LLC acquired a new position in iBio in the first quarter valued at about $2,436,000. Finally, Opaleye Management Inc. acquired a new position in iBio in the first quarter valued at about $2,761,000. 7.90% of the stock is owned by institutional investors and hedge funds.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
See Also
- Five stocks we like better than iBio
- Canadian Penny Stocks: Can They Make You Rich?
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- How to Invest in the FAANG Stocks
- Has This Leading Tech Stock Halted the AI Surge?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.